Mid-year update

Drug regulators in France and Canada announced new warnings. A popular podcast discussed post-finasteride syndrome, while men’s fitness influencers urged followers to avoid finasteride.

A rundown of new bibliographies & research guides

The research base spans many disciplines and goes back almost 50 years. To help researchers get oriented, an on-ramp was added. In the Systems & functions area, a new bibliography was added: Adverse effects on skin, comprising nine case reports. The gynecomastia bibliography has been expanded. The bibliography on the musculoskeletal system has been expanded … Read more

Recent developments

In June 2022, the FDA required the addition of ‘suicidal ideation and behavior’ to the Propecia (finasteride 1 mg) label. In July, France’s national drug regulator ANSM added materials to help patients better understand the risks of finasteride.

News – August 2021

SUMMARY The Sexual Medicine Society of North America hosted a webinar including a talk about sexual dysfunction induced by finasteride and SSRIs. A study by Baylor researchers finding altered gene expression in post-finasteride patients was published in the Journal of Sexual Medicine. The FDA added a new adverse event to the Propecia label: Hematospermia. The … Read more